Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 16 (8) , 563-578
- https://doi.org/10.2165/00023210-200216080-00005
Abstract
No abstract availableKeywords
This publication has 78 references indexed in Scilit:
- Disability indices, the economic costs of illness, and social insurance: The case of multiple sclerosisActa Neurologica Scandinavica, 2009
- A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex®), IFNβ-1b (Betaseron®), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapyMultiple Sclerosis Journal, 2001
- Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MSMultiple Sclerosis Journal, 2001
- Axonal Transection in the Lesions of Multiple SclerosisNew England Journal of Medicine, 1998
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Immunological Aspects of Demyelinating DiseasesAnnual Review of Immunology, 1992
- Multiple sclerosis: Possible immunological mechanismsClinical Immunology and Immunopathology, 1989
- A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple SclerosisNew England Journal of Medicine, 1987
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983